Overview

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The objective of this study was to compare the pharmacokinetics of dipyridamole in three different Asasantin ER batches (test) containing different amounts of retarding lacquers to the existing commercial product at steady state with b.i.d. treatment

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Aspirin, Dipyridamole Drug Combination
Dipyridamole